Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?

Autores
Fassio, Eduardo; Barreyro, Fernando Javier; Pérez, Mariana Soledad; Dávila, Diana; Landeira, Graciela; Gualano, Gisela; Ruffillo, Gabriela
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature recently proposed by a panel of international experts so that the entity is defined based on positive criteria and linked to pathogenesis, replacing the traditional non-alcoholic fatty liver disease (NAFLD), a definition based on exclusion criteria. NAFLD/MAFLD is currently the most common form of chronic liver disease worldwide and is a growing risk factor for development of hepatocellular carcinoma (HCC). It is estimated than 25% of the global population have NAFLD and is projected to increase in the next years. Major Scientific Societies agree that surveillance for HCC should be indicated in patients with NAFLD/ MAFLD and cirrhosis but differ in non-cirrhotic patients (including those with advanced fibrosis). Several studies have shown that the annual incidence rate of HCC in NAFLD-cirrhosis is greater than 1%, thus surveillance for HCC is cost-effective. Risk factors that increase HCC incidence in these patients are male gender, older age, presence of diabetes and any degree of alcohol consumption. In non-cirrhotic patients, the incidence of HCC is much lower and variable, being a great challenge to stratify the risk of HCC in this group. Furthermore, large epidemiological studies based on the general population have shown that diabetes and obesity significantly increase risk of HCC. Some genetic variants may also play a role modifying the HCC occurrence among patients with NAFLD. The purpose of this review is to discuss the epidemiology, clinical and genetic risk factors that may influence the risk of HCC in NAFLD/MAFLD patients and propose screening strategy to translate into better patient care.
Fil: Fassio, Eduardo. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Barreyro, Fernando Javier. Universidad Nacional de Misiones; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
Fil: Pérez, Mariana Soledad. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Dávila, Diana. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Landeira, Graciela. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Gualano, Gisela. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Ruffillo, Gabriela. Hospital Nacional Profesor Alejandro Posadas; Argentina
Materia
HEPATOCELLULAR CARCINOMA
INCIDENCE OF HEPATOCELLULAR CARCINOMA
METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
NONALCOHOLIC STEATOHEPATITIS
SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/215929
Acceder
id CONICETDig_1d3a62357b2cebb57f9942fcdad7d86b
oai_identifier_str oai:ri.conicet.gov.ar:11336/215929
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?Fassio, EduardoBarreyro, Fernando JavierPérez, Mariana SoledadDávila, DianaLandeira, GracielaGualano, GiselaRuffillo, GabrielaHEPATOCELLULAR CARCINOMAINCIDENCE OF HEPATOCELLULAR CARCINOMAMETABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASENONALCOHOLIC STEATOHEPATITISSURVEILLANCE FOR HEPATOCELLULAR CARCINOMAhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature recently proposed by a panel of international experts so that the entity is defined based on positive criteria and linked to pathogenesis, replacing the traditional non-alcoholic fatty liver disease (NAFLD), a definition based on exclusion criteria. NAFLD/MAFLD is currently the most common form of chronic liver disease worldwide and is a growing risk factor for development of hepatocellular carcinoma (HCC). It is estimated than 25% of the global population have NAFLD and is projected to increase in the next years. Major Scientific Societies agree that surveillance for HCC should be indicated in patients with NAFLD/ MAFLD and cirrhosis but differ in non-cirrhotic patients (including those with advanced fibrosis). Several studies have shown that the annual incidence rate of HCC in NAFLD-cirrhosis is greater than 1%, thus surveillance for HCC is cost-effective. Risk factors that increase HCC incidence in these patients are male gender, older age, presence of diabetes and any degree of alcohol consumption. In non-cirrhotic patients, the incidence of HCC is much lower and variable, being a great challenge to stratify the risk of HCC in this group. Furthermore, large epidemiological studies based on the general population have shown that diabetes and obesity significantly increase risk of HCC. Some genetic variants may also play a role modifying the HCC occurrence among patients with NAFLD. The purpose of this review is to discuss the epidemiology, clinical and genetic risk factors that may influence the risk of HCC in NAFLD/MAFLD patients and propose screening strategy to translate into better patient care.Fil: Fassio, Eduardo. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Barreyro, Fernando Javier. Universidad Nacional de Misiones; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; ArgentinaFil: Pérez, Mariana Soledad. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Dávila, Diana. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Landeira, Graciela. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Gualano, Gisela. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Ruffillo, Gabriela. Hospital Nacional Profesor Alejandro Posadas; ArgentinaBaishideng Publishing Group Inc2022-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/215929Fassio, Eduardo; Barreyro, Fernando Javier; Pérez, Mariana Soledad; Dávila, Diana; Landeira, Graciela; et al.; Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?; Baishideng Publishing Group Inc; World Journal of Hepatology; 14; 2; 2-2022; 354-3711948-5182CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v14.i2.354info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/1948-5182/full/v14/i2/354.htminfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:02:07Zoai:ri.conicet.gov.ar:11336/215929instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:02:07.969CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
title Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
spellingShingle Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
Fassio, Eduardo
HEPATOCELLULAR CARCINOMA
INCIDENCE OF HEPATOCELLULAR CARCINOMA
METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
NONALCOHOLIC STEATOHEPATITIS
SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA
title_short Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
title_full Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
title_fullStr Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
title_full_unstemmed Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
title_sort Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?
dc.creator.none.fl_str_mv Fassio, Eduardo
Barreyro, Fernando Javier
Pérez, Mariana Soledad
Dávila, Diana
Landeira, Graciela
Gualano, Gisela
Ruffillo, Gabriela
author Fassio, Eduardo
author_facet Fassio, Eduardo
Barreyro, Fernando Javier
Pérez, Mariana Soledad
Dávila, Diana
Landeira, Graciela
Gualano, Gisela
Ruffillo, Gabriela
author_role author
author2 Barreyro, Fernando Javier
Pérez, Mariana Soledad
Dávila, Diana
Landeira, Graciela
Gualano, Gisela
Ruffillo, Gabriela
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv HEPATOCELLULAR CARCINOMA
INCIDENCE OF HEPATOCELLULAR CARCINOMA
METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
NONALCOHOLIC STEATOHEPATITIS
SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA
topic HEPATOCELLULAR CARCINOMA
INCIDENCE OF HEPATOCELLULAR CARCINOMA
METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
NONALCOHOLIC STEATOHEPATITIS
SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature recently proposed by a panel of international experts so that the entity is defined based on positive criteria and linked to pathogenesis, replacing the traditional non-alcoholic fatty liver disease (NAFLD), a definition based on exclusion criteria. NAFLD/MAFLD is currently the most common form of chronic liver disease worldwide and is a growing risk factor for development of hepatocellular carcinoma (HCC). It is estimated than 25% of the global population have NAFLD and is projected to increase in the next years. Major Scientific Societies agree that surveillance for HCC should be indicated in patients with NAFLD/ MAFLD and cirrhosis but differ in non-cirrhotic patients (including those with advanced fibrosis). Several studies have shown that the annual incidence rate of HCC in NAFLD-cirrhosis is greater than 1%, thus surveillance for HCC is cost-effective. Risk factors that increase HCC incidence in these patients are male gender, older age, presence of diabetes and any degree of alcohol consumption. In non-cirrhotic patients, the incidence of HCC is much lower and variable, being a great challenge to stratify the risk of HCC in this group. Furthermore, large epidemiological studies based on the general population have shown that diabetes and obesity significantly increase risk of HCC. Some genetic variants may also play a role modifying the HCC occurrence among patients with NAFLD. The purpose of this review is to discuss the epidemiology, clinical and genetic risk factors that may influence the risk of HCC in NAFLD/MAFLD patients and propose screening strategy to translate into better patient care.
Fil: Fassio, Eduardo. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Barreyro, Fernando Javier. Universidad Nacional de Misiones; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
Fil: Pérez, Mariana Soledad. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Dávila, Diana. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Landeira, Graciela. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Gualano, Gisela. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Ruffillo, Gabriela. Hospital Nacional Profesor Alejandro Posadas; Argentina
description Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature recently proposed by a panel of international experts so that the entity is defined based on positive criteria and linked to pathogenesis, replacing the traditional non-alcoholic fatty liver disease (NAFLD), a definition based on exclusion criteria. NAFLD/MAFLD is currently the most common form of chronic liver disease worldwide and is a growing risk factor for development of hepatocellular carcinoma (HCC). It is estimated than 25% of the global population have NAFLD and is projected to increase in the next years. Major Scientific Societies agree that surveillance for HCC should be indicated in patients with NAFLD/ MAFLD and cirrhosis but differ in non-cirrhotic patients (including those with advanced fibrosis). Several studies have shown that the annual incidence rate of HCC in NAFLD-cirrhosis is greater than 1%, thus surveillance for HCC is cost-effective. Risk factors that increase HCC incidence in these patients are male gender, older age, presence of diabetes and any degree of alcohol consumption. In non-cirrhotic patients, the incidence of HCC is much lower and variable, being a great challenge to stratify the risk of HCC in this group. Furthermore, large epidemiological studies based on the general population have shown that diabetes and obesity significantly increase risk of HCC. Some genetic variants may also play a role modifying the HCC occurrence among patients with NAFLD. The purpose of this review is to discuss the epidemiology, clinical and genetic risk factors that may influence the risk of HCC in NAFLD/MAFLD patients and propose screening strategy to translate into better patient care.
publishDate 2022
dc.date.none.fl_str_mv 2022-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/215929
Fassio, Eduardo; Barreyro, Fernando Javier; Pérez, Mariana Soledad; Dávila, Diana; Landeira, Graciela; et al.; Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?; Baishideng Publishing Group Inc; World Journal of Hepatology; 14; 2; 2-2022; 354-371
1948-5182
CONICET Digital
CONICET
url http://hdl.handle.net/11336/215929
identifier_str_mv Fassio, Eduardo; Barreyro, Fernando Javier; Pérez, Mariana Soledad; Dávila, Diana; Landeira, Graciela; et al.; Hepatocellular carcinoma in patients with metabolic dysfunctionassociated fatty liver disease: Can we stratify at-risk populations?; Baishideng Publishing Group Inc; World Journal of Hepatology; 14; 2; 2-2022; 354-371
1948-5182
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v14.i2.354
info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/1948-5182/full/v14/i2/354.htm
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Baishideng Publishing Group Inc
publisher.none.fl_str_mv Baishideng Publishing Group Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269738809425920
score 13.13397

Publicaciones similares